Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A, Middleton, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Corrigenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938599/
https://www.ncbi.nlm.nih.gov/pubmed/31430371
http://dx.doi.org/10.1093/annonc/mdz237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938599/
https://www.ncbi.nlm.nih.gov/pubmed/31430371
http://dx.doi.org/10.1093/annonc/mdz237

Ejemplares similares